Business Wire

Augmented Reality: Patient Experience Trumps Misconceptions Around Injectables

Share

New global research,2 sponsored by Galderma and released today by leading filler brand Restylane®, has revealed the prevalent societal misconceptions and stereotypes facing the aesthetics industry. Forty percent of respondents admitted they would discourage others from using facial injectables to reduce wrinkles or provide volume. A further 34% said they believed the results of such treatments look fake and unnatural.

Despite holding these views, when the same respondents were presented with a range of images of people who had undergone filler treatments, the data told another story. On average, 4 out of 5 people could not always identify those who had received filler.3 This highlights the common misconceptions about these types of treatments and the results they deliver.

The perceptions surrounding the use of temporary fillers stand in stark contrast to those around the use of permanent beauty treatments such as tattoos, body piercings and dental corrections. Tattoos and body piercings are primarily seen as a positive form of self-expression (30% of respondents agreed for tattoos, and 24% for body piercings). Teeth straightening is viewed by 47% of respondents as a great way to enhance your appearance. Meanwhile, over a third of respondents (35%) believe fillers create unrealistic beauty standards and ideals, while 26% feel they can easily become addictive and 24% say they are an extreme option.

However, Restylane patient feedback data shows that 96% of people who used fillers felt their treatment exceeded expectations,4 and 95% of patients had maintained or enhanced the naturalness of their facial expressions after treatment.5,6

 

“This new research by Restylane highlights the perception that people are choosing procedures such as fillers because they lack confidence or are going to extremes to get their desired look. But this just isn’t the case! The vast majority of the clients I see are opting for small, subtle changes that will help them create their own look and feel empowered to be the best version of themselves. In my opinion, these people are inherently self-confident, know their own minds and are simply taking control of their own looks.”

 

DR. LUIZ AVELAR

PLASTIC SURGEON

BELO HORIZONTE, BRAZIL

 

The prevalence of societal judgements and the impact they have on how people behave are laid bare in the study. Only 11% of respondents said they would be supportive if a friend or family member told them they were considering using fillers. In contrast, according to Restylane patient feedback, 99% of those who have received treatment would recommend Restylane to a friend.4,6

Media leads in debunking misconceptions

The results also reveal that people see the media as more progressive in its views about aesthetic treatments. 27% percent of respondents said the media portrays injectables as empowering, while just 13% would personally describe them this way. Adult Gen Z7 respondents displayed a more open-minded attitude toward aesthetic procedures and were more likely to see treatments of this nature as empowering (19% in this age group agreed versus 13% overall). They were almost three times more likely to feel positively toward fillers than those over 55 years old, only 7% of whom agreed. Younger consumers also feel that people seeking injectable treatments are inherently more confident.

 

“I’m finding the newer generation is even more open-minded and interested when it comes to injectables. They consider aesthetic treatments to further define and enhance how they look and feel. Given that Restylane studies show that those who use dermal fillers feel overwhelmingly positive about their treatment, we are likely to see more people using them as a means of empowerment.”

 

STEVEN DAYAN, M.D.

FACIAL PLASTIC SURGEON, PROFESSOR AND DIRECTOR OF DENOVA RESEARCH

CHICAGO, ILLNOIS, U.S.

 

The research appears ahead of a Restylane product placement spot in new action-comedy film Mafia Mamma, directed by Catherine Hardwicke of Twilight fame and co-starring Toni Collette and Monica Bellucci. Mafia Mamma celebrates female empowerment and sees Toni Collette’s character challenging her comically clueless colleagues and their outdated attitudes about the reasons why women chose to undergo aesthetic treatments. While the film uses humor to highlight these stereotypes and the judgements people make about injectables, the attitudinal study highlights how these real-life judgements are still prevalent in society. Such beliefs have a tangible impact on the way people behave toward those considering fillers.

 

“We believe in championing everybody’s right to pursue their own beauty ideals. Our research findings are shining a spotlight on some of the misconceptions people have about aesthetic treatments. In this way, we hope to better equip people to make the decision that is right for them, without worrying about external pressures and judgements.”

 

GERRY MUHLE

HEAD OF GLOBAL BUSINESS UNIT, AESTHETICS

GALDERMA

 

About Restylane®

Restylane is the original non-animal stabilized hyaluronic acid filler with over 26 years of achievement and over 55 million treatments worldwide. NASHA™ and OBT™ technologies make Restylane the world’s most diverse range of fillers to deliver truly individualized results.4,5

The Restylane portfolio of products includes Restylane, Restylane Lyft, Restylane Kysse, Restylane Volyme, Restylane® Defyne, Restylane® Refyne, Restylane® EYELIGHT, Restylane SKINBOOSTERS VITAL and Restylane SKINBOOSTERS VITAL LIGHT.

About Galderma

Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information, visit: www.galderma.com.

Footnotes
1 Injectables are aesthetic products which are injected under the skin for a variety of reasons. These include relaxing muscles to alleviate facial wrinkles and folds, or helping contour areas of the face or body, e.g., by restoring volume or adding projection. They often come in the form of products such as botulinum toxin or HA-fillers.
2 Research was carried out by YouGov surveying 9,733 people across the UK, U.S., Canada, Brazil, Germany and Thailand between January 17 and 27, 2023.
3 Respondents were shown six images of people who had used dermal fillers and were asked to indicate if they think the person in the image had used dermal fillers.
4 Andriopoulos B, et al. Presented at: AMWC Monte Carlo, Monaco. 2019.
5 Phillipp-Dormston W, et al. J Cosmet Dermatol. 2020;19:1600–6.
6 Hilton S, et al. Dermatol Surg. 2018;44:261–9.6
7 Adult Gen Z includes those in the 18-24 age bracket.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Sébastien Cros
Corporate Communications Director
Sebastien.cros@galderma.com
+41 79 529 59 85

Rachel Mooney
Global Franchise Communications
rachel.mooney@galderma.com
+41 76 261 64 41

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye